GlassScriptPhysician profile
Phillip Oberg
NPI 1780174557
$3,717.41
in general payments reported to CMS, 2019-2025
27 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.64 · 2020: $30.33 · 2021: $92.30 · 2022: $765 · 2023: $397 · 2024: $493 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,672 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.73 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,271.14 | 2021-2025 | Overstitch Endoscopic Suturing System, Endovive Low Profile Replacement Button, Overstitch Nxt Endoscopic Suturing System |
| Janssen Biotech, INC. | $317.79 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $304.31 | 2020-2025 | |
| Gilead Sciences, INC. | $266.10 | 2023-2025 | |
| Cook Medical LLC | $223.01 | 2023-2025 | Hemospray |
| Genzyme Corporation | $176.86 | 2024-2025 | |
| Ardelyx, INC. | $151.75 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $133.12 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $131.94 | 2024-2025 | Entyvio, Eohilia |
| Enterra Medical, INC. | $116.32 | 2025 | |
| Pfizer INC. | $91.51 | 2019-2025 | |
| Novo Nordisk INC | $69.74 | 2019-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $63.60 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $57.11 | 2025 | Voquezna |
| Lilly USA, LLC | $44.57 | 2025 | Omvoh |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $44.40 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $39.06 | 2024-2025 | Iqirvo |
| Orphalan INC | $38.51 | 2025 | Cuvrior |
| Qol Medical, LLC | $37.94 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.38 | 2022 | |
| Amgen INC. | $21.37 | 2025 | Uplizna |
| Capsovision, INC. | $19.58 | 2024 | Capsocam Plus |
| Medtronic, INC. | $17.88 | 2025 | Interstim |
| Intercept Pharmaceuticals, INC. | $17.60 | 2025 | |
| Amarin Pharma, INC. | $15.33 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2019 | |
| Tandem Diabetes Care, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Oberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.